Vanguard Group
KRBP

Vanguard Group’s Kiromic BioPharma, Inc. Common Stock KRBP Stock Holding History

Vanguard Group’s Portfolio KRBP Stock Details KRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-9,501
Closed -$244K – 4648
2022
Q1 		$244K Sell
9,501
-370
-4% -$10.9K ﹤0.01% 4510
2021
Q4 		$453K Buy
9,871
+28
+0.3% +$1.91K ﹤0.01% 4444
2021
Q3 		$906K Buy
9,843
+5,866
+147% +$607K ﹤0.01% 4268
2021
Q2 		$574K Buy
3,977
+3,630
+1,046% +$910K ﹤0.01% 4249
2021
Q1 		$98K Buy
+347
New +$102K ﹤0.01% 4319

Other funds holding KRBP

ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group's KRBP Position: Q2 2022 in Review

Vanguard Group sold out of Kiromic BioPharma, Inc. Common Stock (KRBP) in Q2 2022, closing a stake of 9,501 shares — an estimated $244K sold.

Vanguard Group first reported a position in KRBP in Q1 2021 and held it in 5 quarters. The position peaked at $906K in Q3 2021. 17 funds tracked by Wall St. Rank hold KRBP as of Q2 2022.

  • Vanguard Group reported no remaining Kiromic BioPharma, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Vanguard Group sold 9,501 Kiromic BioPharma, Inc. Common Stock shares in Q2 2022, an estimated $244K.
  • Vanguard Group first reported a position in Kiromic BioPharma, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
  • Vanguard Group's Kiromic BioPharma, Inc. Common Stock position peaked at $906K in Q3 2021.
  • 17 funds tracked by Wall St. Rank held Kiromic BioPharma, Inc. Common Stock as of Q2 2022.

Based on Vanguard Group's 13F filing for Q2 2022, filed 12 Aug 2022.